Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of RO6958688 with or without atezolizumab in advanced solid tumors
jRCT2080223708Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of cibisatamab in Nonhematologic neoplasms and solid tumor (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary safety and tolerability of RO6958688 ± atezolizumab.
02
Drugs
cibisatamab
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080223708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223708.